Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative Therapy

Inclusion Criteria: * Participant has a documented diagnosis of a neurologic condition, including but not limited to: traumatic brain injury, cerebral palsy, hypoxic-ischemic encephalopathy, stroke, or other neurologic disorders * Participant has received or is scheduled to receive intranasal therapy using MuSE cell-derived exosomes, MuSE stem cells, or combination therapy administered via the Kurve Therapeutics ViaNase system as part of clinical care outside the study protocol * Baseline serum TNF-α measurement is available or can be obtained prior to treatment * Participant or legally authorized representative is able to provide informed consent * Willingness to participate in follow-up assessments, including laboratory and clinical outcome measures * Stable clinical status for at least 2 weeks prior to baseline assessment Exclusion Criteria: * Active systemic infection at the time of enrollment * Use of systemic immunosuppressive or biologic anti-inflammatory therapies that may significantly alter TNF-α levels within 30 days prior to baseline measurement * Inability to obtain baseline or follow-up TNF-α measurements * Incomplete documentation of treatment type, dose, or administration method * Any medical condition that, in the opinion of the investigator, would interfere with interpretation of study outcomes